Summary & Overview
Multiple Level Combined Anterior and Posterior Spinal Fusion Except Cervical with MCC or Custom-Made Anatomically Designed Interbody Fusion Device: Inpatient Reimbursement Overview
DRG 426 describes multiple level combined anterior and posterior spinal fusion except cervical with Major Complication or Comorbidity or a custom-made anatomically designed interbody fusion device, encompassing complex multilevel thoracolumbar procedures. It matters for inpatient reimbursement because it captures high-resource cases into a higher-weighted payment category under Centers for Medicare & Medicaid Services billing rules.
DRG 426 Overview
DRG 426 covers multiple level combined anterior and posterior spinal fusion procedures excluding the cervical spine when performed with a Major Complication or Comorbidity or with a custom-made anatomically designed interbody fusion device. These cases represent complex multilevel thoracic or lumbosacral reconstructions that typically require extended operative time, advanced instrumentation, and higher resource utilization. For Medicare inpatient reimbursement, this Diagnosis-Related Group groups higher-cost patients into a higher-weighted payment category under Centers for Medicare & Medicaid Services rules. Accurate coding of procedures and comorbidities determines eligibility for this Diagnosis-Related Group and affects hospital payment.
Clinical Trials
- Trials evaluating perioperative strategies to reduce complication rates and length of stay in patients undergoing combined anterior-posterior multilevel non-cervical spinal fusion with major complications or use of custom interbody devices. These studies enroll complex adult spine patients with multilevel degenerative disease, deformity, or instability who require staged or same-setting anterior and posterior approaches and often have significant comorbidities; endpoints include perioperative morbidity, transfusion requirements, ICU utilization, and 30‑ to 90‑day readmissions. Results inform surgical risk mitigation, perioperative care pathways, and resource allocation decisions that directly affect inpatient costs and reimbursement for high‑acuity DRG 426 cases.
- Comparative effectiveness trials assessing fusion constructs, graft materials, and the role of custom-made anatomically designed interbody fusion devices versus standard cages in multilevel anterior-posterior fusion for non-cervical spine. These studies focus on radiographic fusion rates, reoperation frequency, functional outcomes, and device- or technique-related adverse events over 1–2 years in patients with multilevel degenerative disease or deformity; some include subgroup analyses by bone quality or previous surgery. Evidence from such trials guides implant selection and surgical planning, impacting up-front device costs, downstream revision rates, and payer decisions about coverage for custom or higher-cost implants used in DRG 426 patients.
- Longitudinal outcomes and health economics studies examining post-discharge recovery, rehabilitation needs, quality of life, and total episode-of-care costs after complex combined anterior-posterior fusion with MCC or custom interbody devices. These prospective observational or registry-based studies follow high‑risk adults through inpatient rehabilitation, home health use, and 90‑ to 365‑day outcomes to quantify functional recovery trajectories, return-to-work rates, and durable cost-effectiveness of initial interventions. Findings help providers and payers optimize discharge planning, bundle payments, and post-acute services to reduce readmissions and improve value for this high-cost DRG population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.